查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417248

前列腺癌市场报告：2030 年趋势、预测和竞争分析

Prostate Cancer Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

前列腺癌趋势和预测

预计到 2030 年，全球前列腺癌市场将达到 194.7 亿美元，2024 年至 2030 年复合年增长率为 8.7%。该市场的主要驱动因素是前列腺癌发病率的增加导致对先进前列腺治疗的需求增加、透过三期临床试验来推进前列腺癌治疗、增加研发资金以及治疗技术的进步。全球前列腺癌市场的未来看起来充满希望，医院药局、药局和零售药局以及线上药局市场充满机会。

前列腺癌市场洞察

Lucintel 预计 AR标靶治疗将在预测期内达到最高成长。

由于前列腺癌盛行率不断上升、多种治疗方案的可用性、技术发展、定製药物和负担得起的治疗方法，亚太地区将在预测期内实现最高的增长预计

常问问题

Q.1 摄护腺癌的市场规模有多大？

A1. 到2030年，全球前列腺癌市场预计将达到194.7亿美元。

Q.2 前列腺癌市场的成长预测为何：

A2. 2024年至2030年，全球前列腺癌市场预计将以8.7%的复合年增长率成长。

Q.3 影响摄护腺癌市场成长的关键因素有哪些：

A3. 该市场的主要驱动力是前列腺癌发生率不断上升，这推动了对先进前列腺治疗的需求，以及透过III期临床试验推进前列腺癌治疗的进展，以及研发资金和治疗进展的增加技术。

Q4.市场的主要细分市场是：

A4. 前列腺癌市场的未来看起来充满希望，医院药局、药局和零售药局以及线上药局市场都有机会。

Q5.市场的主要企业是：

A5. 与摄护腺癌相关的主要企业如下。

  • Ferring Pharmaceuticals
  • Johnson &Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计 AR标靶治疗将在预测期内达到最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7.由于前列腺癌盛行率不断上升、多种治疗方案的可用性、技术发展、定製药物和负担得起的治疗方法，亚太地区在预测期内将出现最高的增长率，预计将会增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球前列腺癌市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球前列腺癌市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的前列腺癌全球市场
    • 荷尔蒙ADT
    • AR标靶治疗
    • 细胞毒性药物
    • 骨转移
    • 治疗性疫苗
    • PARP抑制剂
    • 激酶抑制剂
    • PSMA 靶向放射性配体
  • 按分销管道分類的前列腺癌市场
    • 医院药房
    • 药局和零售药局
    • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的前列腺癌市场
  • 北美前列腺癌市场
  • 欧洲摄护腺癌市场
  • 亚太地区前列腺癌市场
  • 其他地区前列腺癌市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球前列腺癌市场成长机会
    • 全球前列腺癌市场成长机会（按分销管道）
    • 全球前列腺癌市场按地区成长机会
  • 全球前列腺癌市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球前列腺癌市场的产能
    • 全球前列腺癌市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology
简介目录

Prostate Cancer Trends and Forecast

The future of the global prostate cancer market looks promising with opportunities in the hospital pharmacies, drug store & retail pharmacies, and online pharmacies markets. The global prostate cancer market is expected to reach an estimated $19.47 billion by 2030 with a CAGR of 8.7% from 2024 to 2030. The major drivers for this market are growing incidence of prostate cancer driving the need for advanced prostate treatments, prostate cancer medications advancing through phase III clinical trials, and enhancing funding for research & development and advancements in treatment technology.

A more than 150-page report is developed to help in your business decisions.

Prostate Cancer by Segment

The study includes a forecast for the global prostate cancer by drug class, distribution channel, and region.

Prostate Cancer Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Hormonal ADT
  • AR-Directed Therapies
  • Cytotoxic Agents
  • Bone Metastases
  • Therapeutic Vaccines
  • PARP Inhibitors
  • Kinase Inhibitors
  • PSMA-Targeted Radioligands

Prostate Cancer Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Drug store & Retail Pharmacies
  • Online Pharmacies

Prostate Cancer Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Prostate Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prostate cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prostate cancer companies profiled in this report include-

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • Abbvie
  • Astellas Pharma
  • Astrazeneca
  • Bayer
  • Clovis Oncology
  • Dendreon Pharmaceuticals

Prostate Cancer Market Insights

Lucintel forecasts that AR-directed therapies is expected to witness highest growth over the forecast period.

APAC is expected to witness highest growth over the forecast period due to The increasing prevalence of prostate cancer, the availability of several treatment choices, technical developments, customized medications, and affordable therapy.

Features of the Global Prostate Cancer Market

Market Size Estimates: Prostate cancer market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Prostate cancer market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Prostate cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the prostate cancer market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prostate cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the prostate cancer market size?

Answer: The global prostate cancer market is expected to reach an estimated $19.47 billion by 2030.

Q.2 What is the growth forecast for prostate cancer market?

Answer: The global prostate cancer market is expected to grow with a CAGR of 8.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the prostate cancer market?

Answer: The major drivers for this market are growing incidence of prostate cancer driving the need for advanced prostate treatments, prostate cancer medications advancing through phase III clinical trials, and enhancing funding for research & development and advancements in treatment technology.

Q4. What are the major segments for prostate cancer market?

Answer: The future of the prostate cancer market looks promising with opportunities in the hospital pharmacies, drug store & retail pharmacies, and online pharmacies markets.

Q5. Who are the key prostate cancer market companies?

Answer: Some of the key prostate cancer companies are as follows.

  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Sanofi
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Clovis Oncology

Q6. Which prostate cancer market segment will be the largest in future?

Answer: Lucintel forecasts that ar-directed therapies is expected to witness highest growth over the forecast period.

Q7. In prostate cancer market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to The increasing prevalence of prostate cancer, the availability of several treatment choices, technical developments, customized medications, and affordable therapy

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the prostate cancer market by drug class (hormonal ADT, AR-directed therapies, cytotoxic agents,bone metastases, therapeutic vaccines, PARP inhibitors, kinase inhibitors, and PSMA-targeted radioligands), distribution channel (hospital pharmacies, drug store & retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Prostate Cancer Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Prostate Cancer Market by Drug Class
    • 3.3.1: Hormonal ADT
    • 3.3.2: AR-Directed Therapies
    • 3.3.3: Cytotoxic Agents
    • 3.3.4: Bone Metastases
    • 3.3.5: Therapeutic Vaccines
    • 3.3.6: PARP Inhibitors
    • 3.3.7: Kinase Inhibitors
    • 3.3.8: PSMA-Targeted Radioligands
  • 3.4: Global Prostate Cancer Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Drug store & Retail Pharmacies
    • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Prostate Cancer Market by Region
  • 4.2: North American Prostate Cancer Market
    • 4.2.2: North American Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.3: European Prostate Cancer Market
    • 4.3.1: European Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.3.2: European Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Prostate Cancer Market
    • 4.4.1: APAC Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.4.2: APAC Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Prostate Cancer Market
    • 4.5.1: ROW Prostate Cancer Market by Drug Class: Hormonal ADT, AR-Directed Therapies, Cytotoxic Agents, Bone Metastases, Therapeutic Vaccines ,PARP Inhibitors, Kinase Inhibitors, and PSMA-Targeted Radioligands
    • 4.5.2: ROW Prostate Cancer Market by Distribution Channel: Hospital Pharmacies, Drug store & Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Prostate Cancer Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Prostate Cancer Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Prostate Cancer Market by Region
  • 6.2: Emerging Trends in the Global Prostate Cancer Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Prostate Cancer Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Prostate Cancer Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ferring Pharmaceuticals
  • 7.2: Johnson & Johnson
  • 7.3: Merck
  • 7.4: Pfizer
  • 7.5: Sanofi
  • 7.6: AbbVie
  • 7.7: Astellas Pharma
  • 7.8: AstraZeneca
  • 7.9: Bayer
  • 7.10: Clovis Oncology